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Abstract: Paget's disease, described by Sir James Paget in 1874, is classified as mammary and extramammary. The
mammary type is rare and often associated with intraductal cancer (93-100% of cases). It is more prevalent in
postmenopausal women and it appears as an eczematoid, erythematous, moist or crusted lesion, with or with-
out fine scaling, infiltration and inversion of the nipple. It must be distinguished from erosive adenomatosis of
the nipple, cutaneous extension of breast carcinoma, psoriasis, atopic dermatitis, contact dermatitis, chronic
eczema, lactiferous ducts ectasia, Bowen's disease, basal cell carcinoma, melanoma and intraductal papilloma.
Diagnosis is histological and prognosis and treatment depend on the type of underlying breast cancer.
Extramammary Paget's disease is considered an adenocarcinoma originating from the skin or skin appendages
in areas with apocrine glands. The primary location is the vulvar area, followed by the perianal region, scrotum,
penis and axillae. It starts as an erythematous plaque of indolent growth, with well-defined edges, fine scaling,
excoriations, exulcerations and lichenification. In most cases it is not associated with cancer, although there are
publications linking it to tumors of the vulva, vagina, cervix and corpus uteri, bladder, ovary, gallbladder, liver,
breast, colon and rectum. Differential diagnoses are candidiasis, psoriasis and chronic lichen simplex.
Histopathology confirms the diagnosis. Before treatment begins, associated malignancies should be investigated.
Surgical excision and micrographic surgery are the best treatment options, although recurrences are frequent.
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HISTORY 
Sir James Paget, a British surgeon and physiol-
ogist, first described Paget’s disease in 1874.1 At the
time, he portrayed a disease that presented itching,
excoriation, erythema and liquid nipple discharge and
that was associated with underlying cancer in the
mammary gland. Butlin detailed the peculiar
histopathology two years later. 
CLASSIFICATION
Mammary Paget’s disease 
Extramammary Paget’s disease 
MAMMARY PAGET’S DISEASE (MPD)
EPIDEMIOLOGY
This is a rare disease that corresponds to 1-4.3%
of all breast cancers and is frequently associated with
intraductal, in situ or invasive neoplasms. It is more
prevalent in postmenopausal women, usually after
the sixth decade of life, but it has also been reported in
adolescent and elderly patients.2,3,4 It may affect male
patients, albeit more rarely.
CLINICAL PRESENTATION
The disease has an insidious onset, evolving
over months or years for the most part unilaterally,
although rare bilateral cases have been reported.5 It
starts in the nipple, then extends to the areola, and in
more advanced cases to the surrounding skin, as
eczematoid, erythematous, thickened, moist or crust-
ed lesions, with irregular borders, with or without fine
scaling, induration, infiltration, secretion, bleeding,
ulceration and nipple invagination (Figure 1).6 In
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some cases the aspect is psoriasiform, in others it sim-
ulates inflammatory and eczematous conditions;
hyperpigmented lesions similar to superficial spread-
ing melanoma have been reported. It is often asymp-
tomatic at the beginning, but during evolution pruri-
tus, burning sensation and pain can be present. In
very advanced stages, serous and/or bloody papillary
discharge, as well as destruction of the papillary-areo-
lar complex may be observed. At the time of diagno-
sis, lesions’ diameters vary from 0.3 to 15 cm. The dis-
ease can also occur in ectopic breasts and accessory
nipples.7
Between 93-100% of MPD cases are associated
with underlying breast cancer, usually central and
multifocal tumors, mainly located near the areola. In
nearly half the affected patients there is a palpable
tumor mass in the breast, characterized as an invasive
tumor. When this mass is not clinically evident, intra-
ductal cancers are in situ.8,9 It may affect male patients
and the clinical characteristics are similar to those
occurring in women.10,11
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FIGURE 1: 
A: Initial mam-
mary Paget’s
diseas. Observe
u n i l a t e r a l
i n v o l v e m e n t
on right nipple.
B - D e t a i l e d
depiction on
the previous
figure (Cour-
tesy from Dr.
Samuel Freire
da Silva) C-
M a m m a r y
Paget’s disease
also affecting
the areola  
INVESTIGATION OF ASSOCIATED BREAST
CANCER
Confronted with a diagnosis of MPD, it is
essential to investigate mammary gland neoplasm.
This type of cancer may be in situ or invasive, but it is
almost always present. A careful clinical examination
and imaging exams assessment are necessary for diag-
nostic conclusion.
Mammograms can detect masses or calcifica-
tions that represent invasive or in situ ductal carcinoma,
especially when these lesions are palpable. However, a
negative exam does not exclude the presence of
tumors. Some studies report rates of mammographical-
ly occult neoplasms ranging from 15 to 65%.12,13
Ultrasound is particularly useful in cases with
negative mammograms. However, findings are non-
specific, showing only parenchymal heterogeneity,
hypoechoic areas, discrete masses, cutaneous thicken-
ing and ductal dilation. Magnetic resonance is highly
sensitive for the diagnosis of breast neoplasms, espe-
cially if mammography and ultrasound are normal. It
may demonstrate thickening of the papillary-areolar
complex, increase in nipple size, detection of in situ
ductal lesions and invasive tumors, even in clinically
unsuspected cases.14
HISTOPATHOLOGY
MPD is histopathologically characterized by
epidermal Paget cells, which are malignant glandular
epithelial cells with abundant and clear cytoplasm,
usually containing mucin, and pleomorphic and
hyperchromatic nucleus. These cells appear organized
in groups, with nest-like patterns or gland-like struc-
tures, and are preferably located in the epidermal
basal layer. The number of cells varies from a few to
large quantities; even completely replacing the epider-
mal cells. Invasion of adnexal structures can occur.
Ortho-and parakeratosis may be present. The dermis
displays reactive characteristics, with telangiectasia,
chronic inflammation and ulceration in more
advanced cases. 
Figure 2 shows histopathological findings of
epidermal Paget’s disease and in situ dermal ductal
carcinoma in the same biopsy sample.
Immunohistochemistry is very useful in MPD
for differential diagnoses and histogenesis.
Overexpression of the low molecular weight cytoker-
atins, notably CK7, and lack of expression of high
molecular weight cytokeratins, such as CK10, CK14
and CK20 are observed.15,16 Paget cells have the same
immunohistochemical staining pattern as the under-
lying breast cancer cells. Furthermore, they also
express carcinoembryonic antigen, epithelial mem-
brane antigen, and some mucins. Since breast cancers
associated to MPD are poorly differentiated, estrogen
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and progesterone antigens are frequently negative.
Mori et al found overexpression of oncogenic ras and
p21 in mammary and extramammary diseases.17 Paget
cells express p53, p21, Ki-67, cyclin D1, androgen
receptors and Her-2 oncoprotein.18-22 Recent studies
have shown that the expression of NY-BR-1, a breast
differentiation antigen, may have a role in MPD’s
pathogenesis.23
HISTOGENESIS
The histogenesis of MPD is controversial. There
are two main hypotheses that try to explain it and a
third that would represent the combination of them: 
- Epidermotropic Theory 
- Degeneration of Pre-Existing Cells Theory
Epidermotropic theory states that Paget cells
would be cells from the generally present underlying
intraductal cancer that migrated through the basement
membrane to the nipple. Furthermore, recent studies
have shown that, in most cases, there is considerable
similarity in immunohistochemical staining between
MPD and the associated intraductal cancer.24 In sup-
port of this theory, authors detected an overexpression
of Her-2 protein in Paget cells suggesting that ker-
atinocytes would synthesize heregulin-alpha, a mobil-
ity factor that would attract Paget cells to the nipple.25
The second theory, the degeneration of pre-
existing cells, considers that Paget cells are ker-
atinocytes that have undergone malignant transfor-
mation and that the disease is an in situ carcinoma
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regardless of the underlying intraductal carcinoma.26
Proponents of this theory argue that ultrastructural
studies have found microvilli and desmosomes
between Paget cells and local keratinocytes.27 Further
studies are needed to reach a definitive conclusion.
A third theory attempts to combine the two pre-
vious ones, suggesting that Paget cells can originate in
both ways already mentioned, depending on local cir-
cumstances.28 The frequent expression of breast differ-
entiation antigen NY-BR-1 was demonstrated in a
recent study in MPD and EMPD, suggesting that it
may be used as a marker for these diseases.29
DIAGNOSIS
All unilateral persistent inflammatory lesions,
located in the nipple and/or areola should prompt an
investigation for MPD.30
Diagnosis is clinical and histopathological.
Biopsy can be performed by “shaving”, “punch” or
incisional techniques, the latter being the most appro-
priate one. It is essential that the sample contains part
of the lactiferous duct and if the areola is affected, it
also needs to be represented in the sample to confirm
the diagnosis. Often histological exams are inconclu-
sive and more biopsies, or even surgical removal of
the entire nipple may be required. The main histolog-
ical characteristic is the presence of Paget cells, which
are arranged in solid groups. On occasion, they form
glandular arrangements outlining the basal epidermis
and exhibit migration to the granular layer, similarly
to melanocytes. Immunohistochemical methods, such
as CK7, Her-2 oncoprotein and carcinoembryonic
antigen, in addition to histochemical methods for acid
mucin (colloidal iron, Alcian Blue and Mayer’s muci-
carmine) can be used for diagnostic conclusion,
although negative results do not exclude the possibil-
ity. CK7 and Her-2 are considered specific and sensi-
tive MPD markers.31 In 2013, Crignis et al made  a der-
moscopic study of polarized light in a classic case of
MPD (non-pigmented) and found the presence of
“chrysalis-like” structures, a feature described lately
in the literature but not yet reported in MPD cases.32
One study was recently published on the use of con-
focal microscopy in 10 patients with MPD and EMPD,
with satisfactory results.33
DIFFERENTIAL DIAGNOSES
Erosive adenomatosis of the nipple can simu-
late MPD when the latter is circumscribed to the nip-
ple. The chronic evolution and histopathological
results make the diagnosis. Cutaneous extension of a
mammary carcinoma is rare and should be suspected
in case of nipple retraction or adherence. Once more,
histopathological results set the diagnosis.
Differential diagnoses should also be made with
FIGURE 2: 
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inflammatory diseases, including psoriasis, atopic
dermatitis, chronic contact dermatitis and lactiferous
duct ectasia. Bowen’s disease, superficial and page-
toid basal cell carcinoma, superficial spreading
melanoma (if there is hyperpigmentation) and benign
intraductal papilloma, should also be considered.34
Because of the clinical resemblance between MPD and
these diseases, often the diagnosis is not made or is
delayed, with consequent worsening of the prognosis.
PROGNOSIS
Some factors indicate an unfavorable prognosis,
among them: the presence of a palpable breast tumor,
enlarged lymph nodes, histological type of breast can-
cer and patients younger than 60 years. When there is
a palpable breast mass, almost always the carcinoma is
invasive and associated with high rates of axillary
lymph node metastases. Lymph node involvement is
correlated with median survival rates, reaching 75-
95% when negative and 20 to 25% when positive. In
another study, the mean 10-year survival rate was esti-
mated at 47% in cases with positive lymph nodes and
93% in those with negative lymph nodes.35 When the
disease occurs in males, the prognosis is poor, with an
average 5-year survival rate of 20-30%.
TREATMENT
Treatment depends on clinical, radiological and
histopathological features of the associated breast can-
cer, and on metastatic lymph node involvement.
Mastectomy with or without axillary lymph node dis-
section, even in the absence of other malignancy signs,
is considered the best therapy for MPD.
Recently, with the increase in early diagnosis in
breast cancer, multiple prospective randomized trials
were conducted showing that more conservative sur-
gical treatments are possible alternatives, if the dis-
ease is limited to the central segment of the breast.
Among those therapies are: partial or total exclusive
nipple excision, central segmentectomy alone or fol-
lowed by radiation therapy, and radiotherapy without
surgical resection.34,35,36,37 Since these are not yet estab-
lished therapies, if they are adopted patients should
be followed closely, even with regular mammograms.
Complementary treatments depend on the final
tumor staging and lymph node metastases.
EXTRAMAMMARY PAGET’S DISEASE 
HISTORY
In 1889, Radcliffe Crocker first described extra-
mammary Paget’s disease (EMPD) in a patient with
urinary bladder carcinoma, who presented an
eczematous lesion on the penis and scrotum. Darier
and Coulillaud described the perianal location of
EMPD in 1893.
HISTOGENESIS
It is considered a rare adenocarcinoma that
originates from the skin or skin appendages in areas
with apocrine glands. It is believed that, the disease
originates from pluripotent stem cells and it has clini-
cal and histological features similar to MPD.
EPIDEMIOLOGY
The exact incidence is not known, although it is
more common in Caucasian postmenopausal women.
In a study with 1,439 patients, the authors reported
965 women and 474 men, with mean age of 72 years
(range 63-79). The majority was Caucasian.38
CLASSIFICATION
EMPD classification is based on the presence or
absence of associated malignancies:
1. Primary or intraepithelial
2. Secondary
The secondary type is associated with underly-
ing carcinoma or distant tumors.38,39
CLINICAL PRESENTATION
The main anatomical location is the vulva, with
65% of cases, followed by the perianal region (which
is more frequent in males), scrotum, penis and axilla
(Figures 3, 4 and 5).39 In most cases, it is an intra-
epithelial lesion not associated with any underlying or
distant cancer. There are, however, several publica-
tions linking vulvar EMPD with cancer of the vulva,
vagina, cervix and uterus, bladder, ovary, gallbladder,
liver, breast, colon and rectum, in rates that vary from
4-20%.40,41 The anorectal location is mostly associated
with stomach, breast and colorectal carcinomas.
FIGURE 3: 
Vulvar Paget’s
disease
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Primary EMPD can evolve to invasive adenocarcino-
ma, with inherent metastatic potential to regional
lymph nodes and distant organs.38
The disease appears as an erythematous
plaque, with indolent growth, very well defined bor-
ders and the presence of fine scales. It may be asymp-
tomatic or present various degrees of burning sensa-
tion and pruritus, which may even lead to the appear-
ance of excoriations, exulcerations and lichenification.
In the later stages, it may become infiltrated. This dis-
ease is usually multifocal with sub -clinical extension,
which sometimes hinders the establishment of precise
limits with normal skin.
DIAGNOSIS AND DIFFERENTIAL DIAGNOSES
Diagnosis is clinical and must be confirmed by
histopathology. Confocal microscopy was useful in
the diagnosis of a few cases, as recently published.42
Histopathology reveals the presence of Paget cells in
the epidermis, as seen in Figures 6A and 6B. When
histochemical reactions for acid mucin, such as Alcian
Blue, colloidal iron and mucicarmine Mayer are used,
the presence of this substance is detected in the cyto-
plasm of neoplastic cells. Immunohistochemical
examination is very important to the differential diag-
noses with Bowen’s disease, amelanotic superficial
spreading melanoma and to determine whether it is a
primary or secondary disease.43 Cutaneous melanoma
expresses Melan A, S100 and HMB45 but not the other
antibodies, while Bowen’s disease expresses AE1AE3,
p63 and eventually CK7 (Figure 7). The immunohisto-
chemical marker GCDFP-15 (or BRST2) is expressed
in 50% of cases of primary EMPD and it is negative in
secondary types.44 Figure 8 shows focal positivity for
this marker in EMPD.
Depending on the morphological aspects
found, especially absence of glandular arrangement
patterns and only Pagetoid migration through epider-
mic layers besides lack of melanin pigment in amelan-
otic melanoma, a more detailed investigation of the
neoplasm is necessary to exclude other differential
diagnoses (Table 1). Langerhans cell histiocytosis,
FIGURE 4: Paget’s disease affecting vulva, perineal region
and part of the inguinocrural sulcus 
FIGURE5A AND5B:
Extramammary
Paget’s disease
in male genitals
A
B
A
B
FIGURE 6:A:
Epidermis sho-
wing intense
thickening due
to the prolifera-
tion of atypical
cells in Paget’s
disease (HE,
40x).   B:
P a g e t o i d
migration of
atypical epithe-
lial cells, near
the granular
layer, some
with a clear
cytoplasm (HE,
400x)
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FIGURE 7: CK7
immunoreac-
tivity in seve-
ral neoplastic
cells (400x)
FIGURE 8:
BRST2 or
G C D F P - 1 5
m a r k e r
(gross cystic
disease fluid
protein-15)
with focal
positivity in
E M P D
(400X)
which can be morphologically similar to Paget’s dis-
ease, is another possible differential diagnosis. In this
case there will be immunoreactivity of a specific
marker for Langerhans cells - CD1a, while Paget’s dis-
ease markers will be negative.45
Cutaneous candidiasis, chronic lichen simplex
and psoriasis should also be excluded through direct
mycological examination, mycological culture and
histopathology.
METHODS Primary extramammary Secondary extramammary Bowen’s disease Superficial spreading 
Paget’s disease Paget’s disease melanoma
PAS diastase resistant + + - -
Mayer’s mucicarmine + + - -
Alcian Blue + + - -
Colloidal iron + + - -
Fontana Masson - - - +
Pancytokeratin (AE1AE3) + + + -
CK7 + + + or - -
EMA + + - -
CEA + + - -
GCDFP-15 + - - -
Melan-A - - - +
P63 - - + -
S100 protein - - - +
HMB45 - - - +
TABLE 1: Histological and immunohistochemical differential diagnoses of mammary and extramammary Paget’s disease
TREATMENT
Before any therapeutic measure is taken, a thor-
ough and careful investigation to detect the presence
or absence of associated malignancy is essential, espe-
cially in cases with perianal lesions. Surgical excision
with ample margins and micrographic surgery are the
best treatment options, nonetheless relapses are fre-
quent due to the sub-clinical extent of the disease.
Studies using photodynamic therapy have been pub-
lished, however achieving solely palliative results.46
Imiquimod cream at 5% concentration29, 5% 5-fluo-
rouracil cream, CO2 laser and the association of two or
more therapeutic approaches may also be used, with
variable results.47 Since relapses are very common
with any of the available therapeutic options, close
monitoring for long periods is mandatory.❑
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